- Home
- MCN vs PLX Comparison
MCN vs PLX Comparison
Compare MCN & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCN
- PLX
- Stock Information
- Founded
- MCN 2004
- PLX 1993
- Country
- MCN Canada
- PLX Israel
- Employees
- MCN N/A
- PLX N/A
- Industry
- MCN
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCN
- PLX Health Care
- Exchange
- MCN Nasdaq
- PLX Nasdaq
- Market Cap
- MCN 141.5M
- PLX 160.2M
- IPO Year
- MCN N/A
- PLX 1998
- Fundamental
- Price
- MCN $6.67
- PLX $2.22
- Analyst Decision
- MCN
- PLX
- Analyst Count
- MCN 0
- PLX 0
- Target Price
- MCN N/A
- PLX N/A
- AVG Volume (30 Days)
- MCN 52.9K
- PLX 553.9K
- Earning Date
- MCN 01-01-0001
- PLX 03-13-2025
- Dividend Yield
- MCN 9.96%
- PLX N/A
- EPS Growth
- MCN N/A
- PLX N/A
- EPS
- MCN N/A
- PLX N/A
- Revenue
- MCN N/A
- PLX $45,667,000.00
- Revenue This Year
- MCN N/A
- PLX N/A
- Revenue Next Year
- MCN N/A
- PLX $90.00
- P/E Ratio
- MCN N/A
- PLX N/A
- Revenue Growth
- MCN N/A
- PLX N/A
- 52 Week Low
- MCN $6.69
- PLX $0.82
- 52 Week High
- MCN $8.60
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- MCN 41.46
- PLX 74.10
- Support Level
- MCN $6.52
- PLX $2.11
- Resistance Level
- MCN $6.73
- PLX $2.36
- Average True Range (ATR)
- MCN 0.08
- PLX 0.12
- MACD
- MCN 0.01
- PLX 0.00
- Stochastic Oscillator
- MCN 36.00
- PLX 77.42
About MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide a high level of current income and gains, with a secondary objective of capital appreciation.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.